GLPwatch
Papers (10382)
Page 124 of 174, ranked by citation count.
- Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
- Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).
- Characteristics of WBN/Kob diabetic fatty rats supplemented with a fructose-rich diet as a metabolic syndrome model: response to a GLP-1 receptor agonist.
- Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.
- Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF: Evidence for Synergistic Benefit with GLP-1/Glucagon Agonism.
- Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials.
- Drug release profile of a novel exenatide long-term drug delivery system (OKV-119) administered to cats.
- Impacts of tirzepatide on older patients with diminished β-cell function and dementia.
- A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
- GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.
- Comparative cardiovascular effects of GLP-1 agonists using real-world data.
- An overview of randomized clinical trials of fixed-ratio combinations of basal insulin plus GLP-1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes.
- Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
- An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.
- Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.
- Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran.
- Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
- Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review.
- Reframing polycystic ovary syndrome as a complication of obesity: the evolving role of incretin-based therapies.
- Effect of liraglutide on microcirculation in rat model with absolute insulin deficiency.
- Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis.
- Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications.
- Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.
- Liraglutide and Liver Injury: Rare Case Report with Literature Review.
- New Drug: Tirzepatide (Mounjaro<sup>™</sup>).
- Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review.
- Anti-Diabetic Agents and Heart Failure - Response to the CARMELINA Study.
- GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review.
- Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
- Off-label GLP-1 weight-loss medicine use among online bodybuilders: Folk pharmacology, risk and harm reduction.
- Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.
- Tirzepatide: A New Anti-Obesity Medication.
- Liraglutide modulates morpho-functional and inflammatory gastrointestinal responses in rats.
- Letter to the Editor: Comment on "The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial" by Kramer C.K., et al.
- Effectiveness of Low Doses of Semaglutide on Weight Loss and Body Composition Among Women in Their Menopause.
- Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.
- Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.
- Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
- Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes.
- Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis.
- A cost-effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada.
- Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis.
- Add on Exenatide Treatment is Beneficial in Poorly Controlled Obese Type 2 Diabetics under Intensive Insulin Regimens.
- Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
- Exendin-4, a GLP-1 receptor agonist, suppresses diabetic retinopathy <i>in vivo</i> and <i>in vitro</i>.
- GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model.
- Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.
- Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study.
- Applying the Social-Ecological Approach to Evaluate Diabetes Medication Management in Older People.
- Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.
- Semaglutide and health risk: Development and validation of a LC-HRMS method for testing semaglutide in whole blood and application to real cases.
- EGLP-1 lowers body weight better than exendin-4 by reducing food intake and increasing basal energy expenditure in diet-induced obese mice.
- Money being paid for prescribing Wegovy in pilot studies is "over the top," say critics.
- Noninvasive quantitative evaluation of viable islet grafts using <sup>111</sup> In-exendin-4 SPECT/CT.
- GLP-1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy.
- Modeling the impact of preplanned dose titration on delayed response.
- Plastic Surgery in the Ozempidemic: Considerations for the Timing of Body Contouring Surgery in Patients with Semaglutide-Associated Weight Loss.
- GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice.
- Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.
- Safety and Effectiveness of Tirzepatide Use in Obesity Without Type 2 Diabetes Mellitus.